Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.
June 5, 2023
NMPA grants BTD to Innovent’s olverembatinib to treat SDH-deficient GIST
The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted breakthrough therapy designation (BTD) to Innovent Biologics’ olverembatinib for the treatment of succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumour (GIST).
